Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level

Jul 01 2007

Related Content

Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Nov 01 2006

20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships

May 01 2007

Timing is Everything; Tempo Raises Series A

Jun 01 2007

In RNAi, Technology Proliferates Beyond the Big Two

Apr 01 2007

Novartis Opens Door to Broad Dealmaking in RNAi

Oct 01 2005

Related Companies

Roche Holding AG

Alnylam Pharmaceuticals Inc.

Novartis AG

Merck & Co., Inc.

AstraZeneca PLC

Silence Therapeutics plc

GSK plc

Takeda Pharmaceutical Co. Ltd.

Medarex

Archemix Corp.

Sirtris Pharmaceuticals

Sangamo Therapeutics, Inc.

Cerulean Pharma Inc.

Additional Topics

Strategy Business Strategies Legal Issues BioPharmaceutical

More from Business Strategy

More from In Vivo

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window